

Special Issue

Ophthalmic Genetics

Message from the Guest Editors

Inherited retinal disease (IRD) is the leading cause of blindness in the working age population. Advances in molecular genetic techniques, through targeted gene panel analysis with application of next generation sequencing methods, have expedited molecular diagnosis. Similarly, advances in ophthalmic imaging and visual function testing have improved our knowledge of the natural history, which is key to monitoring the treatment effects in clinical trials of novel IRD therapies. Many of these proposed therapies that slow progression or improve retinal function remain under development. Ongoing and upcoming clinical trials emphasise the increasing need for further detailed investigation of the ocular structures and functions in order to better understand the underlying molecular biology of these diseases. The reliability and repeatability of the different assessment modalities is also needed, as well as clearly defined inclusion criteria, prognostic indicators, and trial endpoints. The scope of this Special Issue is the field of ophthalmic genetics, encompassing genomics, molecular biology, therapeutic interventions, and recommended clinical assessments.

Guest Editors

Prof. Kaoru Fujinami
Dr. Michalis Georgiou
Dr. Fred K. Chen

Deadline for manuscript submissions

closed (15 June 2022)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/75385

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))